Blackwood Lindsay K.
Known title: EVP & General CounselCIK: 0001894063
Associated companies
Transaction History
| BCO | ▼ Sell | Tax Withholding | 379 | $34K | 3/3/2025 | View on chart |
| BCO | ▲ Buy | Grant | 2,452 | $0 | 3/3/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 281 | $26K | 3/1/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 373 | $35K | 3/1/2025 | View on chart |
| BCO | ▲ Buy | Grant | 7,566 | $0 | 2/19/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 3,324 | $314K | 2/19/2025 | View on chart |
| BCO | ▲ Buy | Grant | 1,754 | $0 | 2/19/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 756 | $72K | 2/19/2025 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 379 | $31K | 3/3/2024 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 269 | $22K | 3/1/2024 | View on chart |
| BCO | ▲ Buy | Grant | 2,321 | $0 | 3/1/2024 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 1,165 | $96K | 2/24/2024 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 109 | $9K | 2/24/2024 | View on chart |
| BCO | ▲ Buy | Grant | 2,635 | $0 | 3/3/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 226 | $15K | 3/1/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 91 | $6K | 2/24/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 85 | $5K | 2/20/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 709 | $45K | 2/16/2023 | View on chart |
| BCO | ▲ Buy | Grant | 2,542 | $0 | 2/16/2023 | View on chart |
| BCO | ▲ Buy | Grant | 1,719 | $0 | 2/16/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 207 | $12K | 12/15/2022 | View on chart |
| BCO | ▲ Buy | Grant | 1,870 | $0 | 3/1/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 90 | $6K | 2/24/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 92 | $6K | 2/21/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 100 | $7K | 2/20/2022 | View on chart |
| BCO | ▲ Buy | Grant | 1,162 | $0 | 2/17/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 482 | $33K | 2/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy
Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.